Adma Biologics reported $58.74M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Adma Biologics USD 58.74M 14.75M Sep/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
Dynavax Technologies USD 35.53M 10.9M Sep/2025
Takeda JPY 448.13B 173.98B Dec/2025